The 4th Global Biopharmaceutical Frontier Technology Conference and Exhibition is Open for Registration! The story of the “magic bullet” ADC has clearly not reached its final chapter. With the advent of DS-8201, the global ADC market has become exceptionally vibrant, entering a period of rapid growth. The market’s enthusiasm for ADCs is evident from the … Read more
Expert Commentary Professor Feng Jifeng Chief Physician, Professor, Doctoral Supervisor Secretary of the Party Committee, Jiangsu Provincial Cancer Hospital/Nanjing Medical University Affiliated Cancer Hospital Member of the Expert Committee on Rational Drug Use, National Health Commission Council Member of the Chinese Medical Association, Member of the Internal Medicine Group of the Oncology Branch Vice President … Read more
Currently, 15 ADC drugs have been approved globally, of which 6 are approved in China, namely Enfortumab vedotin, Brentuximab vedotin, Trastuzumab deruxtecan, Gemtuzumab ozogamicin, Sacituzumab govitecan, and Loncastuximab tesirine. This article provides a brief summary of the currently approved ADC drugs, the types of tumors they are suitable for, and how to use them. 1. … Read more